Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA
Status:
Not yet recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
AION is the main cause of blindness in patients with GCA. High dose steroid is the reference
treatment of this condition, but medical unmet need remains. Subcutaneous tocilizumab, a
targeted biotherapy, recently received marketing authorization for the treatment of GCA, but
only demonstrated at yet that it can allow steroid dose sparing. The aim of this study is to
assess the benefit of tocilizumab and IV steroids combination or IV steroids alone, in the
treatment of AION due to GCA.
Phase:
Phase 2
Details
Lead Sponsor:
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts